|
1
|
Chirico A, D'Aiuto G, Penon A, Mallia L,
DE Laurentiis M, Lucidi F, Botti G and Giordano A: Self-efficacy
for coping with cancer enhances the effect of reiki treatments
during the pre-surgery phase of breast cancer patients. Anticancer
Res. 37:3657–3665. 2017.PubMed/NCBI
|
|
2
|
Pu Z, Zhang X, Chen Q, Yuan X and Xie H:
Establishment of an expression platform of OATP1B1 388GG and 521CC
genetic polymorphism and the therapeutic effect of tamoxifen in
MCF-7 cells. Oncol Rep. 33:2420–2428. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gokal K, Wallis D, Ahmed S, Boiangiu I,
Kancherla K and Munir F: Effects of a self-managed home-based
walking intervention on psychosocial health outcomes for breast
cancer patients receiving chemotherapy: A randomised controlled
trial. Support Care Cancer. 24:1139–1166. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhu H, Dai M, Chen X, Chen X, Qin S and
Dai S: Integrated analysis of the potential roles of miRNAmRNA
networks in triple negative breast cancer. Mol Med Rep.
16:1139–1146. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tanaka H, Hazama S, Iida M, Tsunedomi R,
Takenouchi H, Nakajima M, Tokumitsu Y, Kanekiyo S, Shindo Y,
Tomochika S, et al: miR-125b-1 and miR-378a are predictive
biomarkers for the efficacy of vaccine treatment against colorectal
cancer. Cancer Sci. 108:2229–2238. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Murphy JP and Pinto DM: Temporal proteomic
analysis of IGF-1R signalling in MCF-7 breast adenocarcinoma cells.
Proteomics. 10:1847–1860. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kucab JE and Dunn SE: Role of IGF-1R in
mediating breast cancer invasion and metastasis. Breast Dis.
17:41–47. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Heskamp S, van Laarhoven HW,
Molkenboer-Kuenen JD, Franssen GM, Versleijen-Jonkers YM, Oyen WJ,
van der Graaf WT and Boerman OC: ImmunoSPECT and immunoPET of
IGF-1R expression with the radiolabeled antibody R1507 in a
triple-negative breast cancer model. J Nucl Med. 51:1565–1572.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kalder M, Kyvernitakis I, Albert US,
Baier-Ebert M and Hadji P: Effects of zoledronic acid versus
placebo on bone mineral density and bone texture analysis assessed
by the trabecular bone score in premenopausal women with breast
cancer treatment-induced bone loss: Results of the ProBONE II
substudy. Osteoporos Int. 26:353–360. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Barbie TU, Alexe G, Aref AR, Li S, Zhu Z,
Zhang X, Imamura Y, Thai TC, Huang Y, Bowden M, et al: Targeting an
IKBKE cytokine network impairs triple-negative breast cancer
growth. J Clin Invest. 124:5411–5423. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Danza K, Summa S, Pinto R, Pilato B,
Palumbo O, Carella M, Popescu O, Digennaro M, Lacalamita R and
Tommasi S: TGFbeta and miRNA regulation in familial and sporadic
breast cancer. Oncotarget. 8:50715–50723. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Piperigkou Z, Franchi M, Gotte M and
Karamanos NK: Estrogen receptor beta as epigenetic mediator of
miR-10b and miR-145 in mammary cancer. Matrix Biol. 64:94–111.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu J, Wang JG, Zhang L, Yang HP, Wang L,
Ding D, Chen Q, Yang WL, Ren KH, Zhou DM, et al: MicroRNA-320a
inhibits breast cancer metastasis by targeting metadherin.
Oncotarget. 7:38612–38625. 2016.PubMed/NCBI
|
|
14
|
Ren JG, Seth P, Ye H, Guo K, Hanai JI,
Husain Z and Sukhatme VP: Citrate suppresses tumor growth in
multiple models through inhibition of glycolysis, the tricarboxylic
acid cycle and the IGF-1R pathway. Sci Rep. 7:45372017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li ZH, Xiong QY, Xu L, Duan P, Yang QO,
Zhou P and Tu JH: miR-29a regulated ER-positive breast cancer cell
growth and invasion and is involved in the insulin signaling
pathway. Oncotarget. 8:32566–32575. 2017.PubMed/NCBI
|
|
16
|
Guo T, Feng Y, Liu Q, Yang X, Jiang T,
Chen Y and Zhang Q: MicroRNA-320a suppresses in GBM patients and
modulates glioma cell functions by targeting IGF-1R. Tumour Biol.
35:11269–11275. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lin Y, Deng W, Pang J, Kemper T, Hu J, Yin
J, Zhang J and Lu M: The microRNA-99 family modulates hepatitis B
virus replication by promoting IGF-1R/PI3K/Akt/mTOR/ULK1
signaling-induced autophagy. Cell Microbiol. 19:2017. View Article : Google Scholar
|
|
18
|
Ma Y, Fu S, Lu L and Wang X: Role of
androgen receptor on cyclic mechanical stretch-regulated
proliferation of C2C12 myoblasts and its upstream signals:
IGF-1-mediated PI3K/Akt and MAPKs pathways. Mol Cell Endocrinol.
450:83–93. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Iskender B, Izgi K, Sakalar C and Canatan
H: Priming hMSCs with a putative anti-cancer compound,
myrtucommulone-a: A way to harness hMSC cytokine expression via
modulating PI3K/Akt pathway? Tumour Biol. 37:1967–1981. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hashimoto K, Tsuda H, Koizumi F, Shimizu
C, Yonemori K, Ando M, Kodaira M, Yunokawa M, Fujiwara Y and Tamura
K: Activated PI3K/AKT and MAPK pathways are potential good
prognostic markers in node-positive, triple-negative breast cancer.
Ann Oncol. 25:1973–1979. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu C, Liu Z, Li X, Tang X, He J and Lu S:
MicroRNA-1297 contributes to tumor growth of human breast cancer by
targeting PTEN/PI3K/AKT signaling. Oncol Rep. 38:2435–2443. 2017.
View Article : Google Scholar : PubMed/NCBI
|
